TY - JOUR
T1 - Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades
AU - Ochi, Nobuaki
AU - Hotta, Katsuyuki
AU - Takigawa, Nagio
AU - Oze, Isao
AU - Fujiwara, Yoshiro
AU - Ichihara, Eiki
AU - Hisamoto, Akiko
AU - Tabata, Masahiro
AU - Tanimoto, Mitsune
AU - Kiura, Katsuyuki
PY - 2012/8/6
Y1 - 2012/8/6
N2 - Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time. Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis. Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95%. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033). Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.
AB - Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time. Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis. Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95%. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033). Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.
UR - http://www.scopus.com/inward/record.url?scp=84864717387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864717387&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0042798
DO - 10.1371/journal.pone.0042798
M3 - Article
C2 - 22880112
AN - SCOPUS:84864717387
SN - 1932-6203
VL - 7
JO - PLoS One
JF - PLoS One
IS - 8
M1 - e42798
ER -
